IL17A and chronic obstructive pulmonary disease: In conclusion, this study demonstrates the benefits of administering IL-17-neutralizing antibodies in controlling the inflammatory response induced by CS exposure in mice, mitigating both functional and structural changes in a CS-induced COPD model.